Sökning: onr:"swepub:oai:DiVA.org:uu-152144" >
No benefit of treat...
No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy
-
- Axelson, Hans W. (författare)
- Uppsala universitet,Klinisk neurofysiologi
-
- Öberg, Gunnar (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Askmark, Håkan (författare)
- Uppsala universitet,Neurologi
-
(creator_code:org_t)
- 2007-12-12
- 2008
- Engelska.
-
Ingår i: Acta Neurologica Scandinavica. - : Hindawi Limited. - 0001-6314 .- 1600-0404. ; 117:6, s. 432-434
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction - Patients with multifocal motor neuropathy (MMN) usually respond to intravenous immunoglobulin (IVIG), but because of the short-lasting effect the treatment must be given repeatedly. Remission after treatment with high-dose cyclophosphamide has recently been reported in one patient refractory to IVIG. Case report - Here we report on a patient who responded to IVIG, but temporarily deteriorated dramatically after treatment with high-dose cyclophosphamide and autologous blood stem cell transplantation. Today the situation is the same as before the treatment with cyclophosphamide and blood stem cell transplantation, i.e. IVIG is given every 4 weeks. Conclusion - Our patient did not benefit from the treatment with high-dose cyclophosphamide and autologous blood stem cell transplantation. The effect of treatment with high-dose cyclophosphamide in MMN seems to be difficult to predict and that should be paid attention to if this type of treatment is considered.
Nyckelord
- multifocal motor neuropathy
- MMN
- treatment
- cyclophosphamide
- blood stem cell transplantation
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas